Drug Trial Radar · NCT04681170
Efficacy and Safety of Lomitapide in Paediatric Patients With Homozygous Familial Hypercholesterolaemia (HoFH)
Last checked: Nov 20, 2026Latest source record: Aug 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
46
Actual
Start
Dec 14, 2020
Primary completion
Oct 16, 2022
Study completion Jun 6, 2024
Sponsor
- Lead sponsor
- Amryt PharmaIndustry
- Sponsor type
- Industry
- First posted
- Dec 23, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 5 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a single arm, open label, multi centre phase III study to evaluate the efficacy and long term safety of lomitapide in paediatric patients with HoFH receiving stable lipid lowering therapy (LLT) (including lipoprotein apheresis (LA), when applicable) comprising of the following phases: * Screening Period (starting at Week 12, i.e. ≤12 weeks prior to Baseline for up to 6 weeks) * Stratified Enrolment and Start of Run in Period (starting at minimum at Week 6, i.e., 6 weeks prior to Baseline for a minimum of 6 weeks): * Efficacy Phase (starting at Baseline, i.e. Day \[D\] 0 for 24 weeks±3 days * Safety Phase (starting at Week 24±3 days for 80±1 weeks)
Conditions
- Homozygous Familial Hypercholesterolaemia (HoFH)
Interventions
LomitapideDrug
2mg,5mg, 10mg and 20mg capsules
Primary outcomes
What the sponsor says the trial is designed to measure.
- Efficacy Endpoint: Percent Change in Low-density Lipoprotein Cholesterol (LDL C) at Week 24 Compared to BaselineTime frame: Baseline through Week 24
Locations
12 sites in 6 countries. Site status is shown where the registry gives one.
University Hospital of Cologne
Cologne, Germany
University Medical Center Hamburg-Eppendorf
Hamburg, Germany
Universtiats-Kinderlinik Heidelberg
Heidelberg, Baden-Wurttemberg, Germany
Chaim Sheba Medical Center
Ramat Gan, Israel
Bambino Gesù Children's Hospital,
Roma, Italy
U.O.C. Clinica Medica 1
Padova, Padua, Italy
King Abdullah International Medical Research Centre (KAIMRC),
Riyadh, Saudi Arabia
King Faisal Specialist Hospital
Riyadh, Saudi Arabia
Hospital Abente y Lago
A Coruña, Spain
Hospital Clinico Universitario of Valencia
Valencia, Spain
Hospital Universitari Sant Joan
Reus, Tarragona,, Spain
E.P.S. Fattouma Bourguiba Hospital
Monastir, Tunisia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.